Swiss National Bank Decreases Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

Swiss National Bank lessened its stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 4.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 119,455 shares of the biotechnology company's stock after selling 5,600 shares during the period. Swiss National Bank owned about 0.27% of United Therapeutics worth $42,149,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Newbridge Financial Services Group Inc. bought a new stake in shares of United Therapeutics in the 4th quarter valued at about $25,000. Brooklyn Investment Group acquired a new position in shares of United Therapeutics in the 3rd quarter valued at about $33,000. MassMutual Private Wealth & Trust FSB lifted its stake in shares of United Therapeutics by 31.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock valued at $85,000 after purchasing an additional 58 shares during the period. Jones Financial Companies Lllp raised its stake in United Therapeutics by 678.9% during the 4th quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company's stock worth $104,000 after buying an additional 258 shares during the period. Finally, SBI Securities Co. Ltd. acquired a new position in United Therapeutics during the 4th quarter worth approximately $131,000. Institutional investors own 94.08% of the company's stock.

Insider Buying and Selling at United Therapeutics

In other news, Director Nilda Mesa sold 255 shares of United Therapeutics stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $355.77, for a total transaction of $90,721.35. Following the completion of the transaction, the director now directly owns 5,528 shares in the company, valued at approximately $1,966,696.56. This trade represents a 4.41 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Michael Benkowitz sold 10,000 shares of the business's stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $356.68, for a total transaction of $3,566,800.00. Following the completion of the transaction, the chief operating officer now owns 2,577 shares of the company's stock, valued at approximately $919,164.36. The trade was a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 90,255 shares of company stock valued at $32,614,521. 11.90% of the stock is currently owned by corporate insiders.

Remove Ads

Wall Street Analysts Forecast Growth

Several analysts have recently commented on UTHR shares. StockNews.com downgraded United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Thursday, February 27th. HC Wainwright reissued a "buy" rating and issued a $425.00 price objective on shares of United Therapeutics in a research note on Thursday, February 27th. Finally, UBS Group increased their price objective on United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a research note on Wednesday, January 8th. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $388.25.

United Therapeutics Trading Down 1.6 %

United Therapeutics stock traded down $5.25 during trading hours on Thursday, hitting $313.60. 327,253 shares of the stock traded hands, compared to its average volume of 443,181. The firm's 50-day moving average price is $347.20 and its two-hundred day moving average price is $357.65. The company has a market cap of $14.08 billion, a PE ratio of 13.77, a PEG ratio of 0.97 and a beta of 0.64. United Therapeutics Co. has a one year low of $221.53 and a one year high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, beating the consensus estimate of $6.10 by $0.09. The business had revenue of $735.90 million for the quarter, compared to analysts' expectations of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same period in the previous year, the firm posted $4.36 EPS. On average, sell-side analysts expect that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.